Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Accumulated Expenses (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Accumulated Expenses for 13 consecutive years, with $260.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 108.82% to $260.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $260.4 million through Dec 2025, up 108.82% year-over-year, with the annual reading at $260.4 million for FY2025, 108.82% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $260.4 million at Madrigal Pharmaceuticals, down from $345.4 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $345.4 million in Q3 2025, with the low at $44.1 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $110.0 million, with a median of $87.8 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses dropped 1.62% in 2023, then skyrocketed 163.64% in 2025.
  • Over 5 years, Accumulated Expenses stood at $55.0 million in 2021, then skyrocketed by 66.15% to $91.5 million in 2022, then dropped by 1.62% to $90.0 million in 2023, then surged by 38.58% to $124.7 million in 2024, then skyrocketed by 108.82% to $260.4 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $260.4 million, $345.4 million, and $157.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.